4LSC4211 [D9]-C16-Sphingomyelin (d18:1/16:0)

Catalog Number: 4LSC4211
CAS #: N/A
Related CAS #: 6254-89-3 (unlabeled)
Name: [D9]-C16-Sphingomyelin (d18:1/16:0) , [D9]-N-Palmitoyl-D-sphingomyelin, [D9]-(2S,3R,4E)-2-(Palmitoylamino)-4-octadecene-3-hydroxy-1-phosphocholine, [D9]-N-(Hexadecanoyl)-sphing-4-enine-1-phosphocholine, [D9]-N-Palmitoyl-D-erythro-sphingosylphosphorylcholine.

In stock !

C16 Sphingomyelin is a naturally occuring sphingolipid. Dysregulated sphingolipid metabolism has become a common theme in a variety of disease, among which cancer and alzheimer disease (AD). For exemple, recent studies have suggested potential utility of plasma sphingolipids as diagnostic and/or prognostic indicator of AD.

Stable isotope Sphingomyelin (4LSC4211, [D9]-C16 Sphingomyelin) is intended for the quantification of C16-Sphingomyelin (4LSC3341) in biological matrices by GC or LC-MS

Keywords:

Clinical chemistry, diagnostic tools & biomarkers, stable isotope dilution analysis, internal standard, stable isotope labeled standard (SIL), therapeutic drug monitoring (TDM), quantitative bioanalytical method validation, clinical diagnostic, LC/MS method validation.

  • Molecular Formula: C39H70N2O6D9P
  • Molecular Weight: 712.09 g/mol
  • Specification:
    • Minimum purity: 95.0 %
    • Minimum Isotopic Enrichment: D ≥98 %
  • HS Code: 284590
  • Packing Size: 1mg, 5mg, 25mg, bulk
  • Solubility: chloroform, warm ethanol, warm methanol
  • Physical Appearance: solid
  • Storage: -20°C

Toledo, Jon, B,  Biomarkers for the diagnosis and characterization of Alzheimer’s disease, WO/2018/049268.

Lin, W., et al. (2017). Studies on diagnostic biomarkers and therapeutic mechanism of Alzheimer’s disease through metabolomics and hippocampal proteomics.  Eur J Pharm Sci 105: 119-126. (DOI: 10.1016/j.ejps.2017.05.003)

Fonteh, A. N., et al. (2015). Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer’s disease.  PLoS One 10(5): e0125597. (DOI: 10.1371/journal.pone.0125597)

Alessenko, A. V. (2013). The potential role for sphingolipids in neuropathogenesis of Alzheimer’s disease. Biomeditsinskaya Khimiya 59(1): 25-50. (DOI: 10.18097/pbmc20135901025)

Han, X., et al. (2011). Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6(7): e21643. (DOI: 10.1371/journal.pone.0021643)

Mielke, M. M. and C. G. Lyketsos (2010). Alterations of the sphingolipid pathway in Alzheimer’s disease: new biomarkers and treatment targets? Neuromolecular Med 12(4): 331-340. (DOI: 10.1007/s12017-010-8121-y)

Kosicek, M., et al. (2010). Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer’s disease patients–a pilot study. Anal Bioanal Chem 398(7-8): 2929-2937. (DOI: 10.1007/s00216-010-4273-8)

Mielke, M. M., et al. (2010). Serum sphingomyelins and ceramides are early predictors of memory impairment.” Neurobiol Aging 31(1): 17-24. (DOI: 10.1016/j.neurobiolaging.2008.03.011)

Varma, V. R., et al. (2018). Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med 15(1): e1002482. (DOI: 10.1371/journal.pmed.1002482)

Olazaran, J., et al. (2015). A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer’s disease. J Alzheimers Dis 45(4): 1157-1173. (DOI: 10.3233/JAD-142925)

Fonteh, A. N., et al. (2006). Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers 22(1-2): 39-64. (DOI: 10.1155/2006/202938)


You may also be interested in the following product: